RESUMEN
The WHO MPOWER package is a set of six evidence-based and cost-effective measures which was introduced on 7 February 2008 to facilitate the implementation of the provisions of the WHO Framework Convention on Tobacco Control at the ground level. These measures are: Monitoring tobacco use and prevention policies (M); Protecting people from tobacco smoke (P); Offering help to quit tobacco use (O); Warning about the dangers of tobacco (W); Enforcing bans on tobacco advertising, promotion and sponsorship (E); and Raising taxes on tobacco (R). Since its launch, the MPOWER package has become the guiding principle for all the countries of the South-East Asia Region in their crusade against the tobacco epidemic. This review article tracks the implementation of the MPOWER measures in the 11 member countries of the Region based on the last seven WHO Report on the Global Tobacco Epidemic (GTCR), i.e., GTCR2/2009-GTCR8/2021. This is with an aim to enable the countries to review their progress in implementing the MPOWER measures and to take steps to improve their advancement towards reducing the demand for tobacco products at the country level.
Asunto(s)
Control de Medicamentos y Narcóticos/métodos , Etiquetado de Productos/métodos , Embalaje de Productos/métodos , Prevención del Hábito de Fumar/métodos , Uso de Tabaco/prevención & control , Asia Sudoriental , Control de Medicamentos y Narcóticos/legislación & jurisprudencia , Epidemias , Salud Global/estadística & datos numéricos , Implementación de Plan de Salud , Política de Salud , Humanos , Etiquetado de Productos/legislación & jurisprudencia , Embalaje de Productos/legislación & jurisprudencia , Cese del Hábito de Fumar/legislación & jurisprudencia , Cese del Hábito de Fumar/métodos , Prevención del Hábito de Fumar/legislación & jurisprudencia , Uso de Tabaco/epidemiología , Organización Mundial de la SaludAsunto(s)
Antiinfecciosos/uso terapéutico , Farmacorresistencia Microbiana , Infecciones por VIH/tratamiento farmacológico , Malaria/tratamiento farmacológico , Tuberculosis/tratamiento farmacológico , Asia Sudoriental/epidemiología , Infecciones por VIH/epidemiología , Humanos , Malaria/epidemiología , Tuberculosis/epidemiologíaRESUMEN
INTRODUCTION: HIV testing is the entry point for the elimination of mother-to-child transmission of HIV. Decreasing external funding for the HIV response in some low- and middle-income countries has triggered the question of whether a focused approach to HIV testing targeting pregnant women in high-burden areas should be considered. This study aimed at determining and comparing the cost-effectiveness of universal and focused HIV testing approaches for pregnant women across high to very low HIV prevalence settings. METHODS: We conducted a modelling analysis on health and cost outcomes of HIV testing for pregnant women using four country-based case scenarios (Namibia, Kenya, Haiti and Viet Nam) to illustrate high, intermediate, low and very low HIV prevalence settings. We used subnational prevalence data to divide each country into high-, medium- and low-burden areas, and modelled different antenatal and testing coverage in each. RESULTS: When HIV testing services were only focused in high-burden areas within a country, mother-to-child transmission rates remained high ranging from 18 to 23%, resulting in a 25 to 69% increase in new paediatric HIV infections and increased future treatment costs for children. Universal HIV testing was found to be dominant (i.e. more QALYs gained with less cost) compared to focused approaches in the Namibia, Kenya and Haiti scenarios. The universal approach was also very cost-effective compared to focused approaches, with $ 125 per quality-adjusted life years gained in the Viet Nam-based scenario of very low HIV prevalence. Sensitivity analysis further supported the findings. CONCLUSIONS: Universal approach to antenatal HIV testing achieves the best health outcomes and is cost-saving or cost-effective in the long term across the range of HIV prevalence settings. It is further a prerequisite for quality maternal and child healthcare and for the elimination of mother-to-child transmission of HIV.